Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Halozyme Therapeutics Inc shares valued at $1,148,618 were sold by Torley Helen on Jul 10 ’25. At $57.43 per share, Torley Helen sold 20,000 shares. The insider’s holdings dropped to 733,719 shares worth approximately $45.73 million following the completion of this transaction.
Also, Torley Helen sold 20,000 shares, netting a total of over 1,128,655 in proceeds. Following the sale of shares at $56.43 each, the insider now holds 733,719 shares.
Before that, Torley Helen had sold 20,000 shares from its account. In a trade valued at $1,110,245, the PRESIDENT AND CEO traded Halozyme Therapeutics Inc shares for $55.51 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $45.73 million.
As published in a research note from Morgan Stanley on August 06, 2025, Halozyme Therapeutics Inc [HALO] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $75. As of May 14, 2025, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for HALO. Earlier on May 13, 2025, Leerink Partners downgraded its rating. Their new recommendation was “an Underperform” for HALO stock which previously was a “a Market perform”.
Analyzing HALO Stock Performance
On last trading session, Halozyme Therapeutics Inc [NASDAQ: HALO] rose 2.48% to $62.32. The stock’s lowest price that day was $61.955, but it reached a high of $65.3999 in the same session. During the last five days, there has been a surge of approximately 3.73%. Over the course of the year, Halozyme Therapeutics Inc shares have jumped approximately 15.22%.
Is Halozyme Therapeutics Inc subject to short interest?
Stocks of Halozyme Therapeutics Inc saw a sharp steep in short interest on 2025-07-15 dropping by -1.46 million shares to 9.6 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 11.07 million shares. A decline of -15.24% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.29 of the overall float, the days-to-cover ratio (short ratio) decline to 3.29.
Which companies own the most shares of Halozyme Therapeutics Inc (HALO)?
In terms of Halozyme Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 1.96% from the previous closing price of $60.81. Analysts anticipate Halozyme Therapeutics Inc stock to reach 62 by 2025, with the lowest price target being 62. In spite of this, 7 analysts ranked Halozyme Therapeutics Inc stock as Buy at the end of 2025. On October 07, 2024, Wells Fargo assigned a price target of “an Equal weight” to the stock and downgraded coverage with a $62.
